Prevention of Fatal Arrhythmia in a Catecholaminergic Polymorphic Ventricular Tachycardia Mouse Model Carrying Calsequestrin Mutation

Ronny Alcalai ^{1,2}, Hiroko Wakimoto ², Michael Arad ³, Lei Song ², Jon Seidman ², Christine Seidman ²

Background Catecholamine-induced polymorphic ventricular tachycardia (CPVT) is a familial syndrome caused by mutations in the ryanodine receptor-2(RyR2) or the calsequestrin-2(CASQ2) genes and characterized by sudden death induced by exercise or emotional stress. Treatment of CPVT patients is limited given that beta-adrenergic blockers were found to be only partially effective and no other agents were broadly tested. Recent studies have shown that CPVT is mediated by increased Ca²⁺ leak through the RyR2 channel. Our aim was to determine whether agents that may inhibit intracellular Ca²⁺ leak can effectively prevent CPVT. **Methods** The efficacy of Ca²⁺ channel blockers, beta-adrenergic blockers and Mg²⁺ were tested using a CPVT mouse model carrying mutation in CASQ2 gene. We assessed the in-vivo prevalence of stress induced arrhythmia at baseline and after short and long-term drug treatment and the drug effect on contractility and Ca2+ transient of isolated cardiomyocytes. Results All study drugs reduced the frequency of stress induced ventricular arrhythmia in mutant mice. Nevertheless, only Verapamil completely prevented arrhythmia in 80% of the mice. Cardiomyocytes studies indicated that both Mg²⁺ and Verapamil inhibited sarcomere contraction, shortened the Ca²⁺ reuptake period and prolonged the caffeine induced Ca²⁺ transients of mutant cardiomyocytes. Diastolic Ca²⁺ overload and Ca²⁺ oscillations that typically present in stressed mutant myocytes were partially prevented by Mg²⁺ and more effectively by Verapamil. Conclusion Verapamil is the most effective agent in preventing ventricular arrhythmia in CPVT mouse model and in modifying the intracellular abnormal calcium handling of mutant cardiomyocytes, probably by inhibiting the intracellular Ca²⁺ leak. Calcium antagonists might have therapeutic value in CPVT and other RvR2 mediated arrhythmias and should be tested in human studies.

¹ Cardiology Department, Hadassah-Hebrew University Medical Centre, Jerusalem, Israel, ² Genetics Department, Harvard Medical School, Boston, USA, ³ Cardiology Department, Sheba Medical Centre and Tel Aviv University, Ramat Gan, Israel